Ignite Creation Date:
2025-12-24 @ 10:10 PM
Ignite Modification Date:
2026-02-27 @ 1:09 AM
Study NCT ID:
NCT02650635
Status:
TERMINATED
Last Update Posted:
2018-09-05
First Post:
2015-12-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Sponsor:
Mayo Clinic
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Colorectal Adenocarcinoma | View |
| None | Metastatic Pancreatic Adenocarcinoma | View |
| None | Recurrent Breast Carcinoma | View |
| None | Recurrent Colorectal Carcinoma | View |
| None | Recurrent Melanoma of the Skin | View |
| None | Recurrent Non-Small Cell Lung Carcinoma | View |
| None | Recurrent Pancreatic Carcinoma | View |
| None | Recurrent Renal Cell Carcinoma | View |
| None | Solid Neoplasm | View |
| None | Stage IV Breast Cancer | View |
| None | Stage IV Non-Small Cell Lung Cancer | View |
| None | Stage IV Renal Cell Cancer | View |
| None | Stage IV Skin Melanoma | View |
| None | Stage IVA Colorectal Cancer | View |
| None | Stage IVA Pancreatic Cancer | View |
| None | Stage IVB Colorectal Cancer | View |
| None | Stage IVB Pancreatic Cancer | View |
Keywords: